DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for pigmented villonodular synovitis — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease modulePigmented villonodular synovitis maps to a 3-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for pigmented villonodular synovitis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
colony stimulating factor 1 receptor (CSF1R) — CSF1R is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet ukidrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8JOT · 1.69 Å · ligand Sulfatinib (UKI). Experimental structure, not a prediction.
What the evidence adds up to
Pigmented villonodular synovitis is a rare benign proliferative disease of the synovial joint, synovial sac and tendon sheath. Its diagnosis is difficult because there are no characteristic etiological factors or clinical manifestations, and because of insufficient knowledge among doctors. A 2022 literature review and case report illustrates this with a case of late diagnosis despite the presence of certain clinical and morphological signs. The aetiology remains unknown. A 1997 report of a father and son both affected suggests that genetic factors might be important, but the main hypotheses remain divided between a response to blood products from chronic repetitive trauma and inflammation from an unknown trigger, with some cytogenetic evidence of clonality supporting a benign neoplastic process while most authors favour a non-neoplastic cause.
Surgery is the usual treatment, but postoperative joint dysfunction and pain are common and seriously affect quality of life. A 2020 protocol for a systematic review and meta-analysis aims to evaluate the effectiveness and safety of acupuncture for these postoperative symptoms. No results from that review are yet available.
No drug treatment for pigmented villonodular synovitis itself is described in these abstracts. There are no response rates, survival figures, or sample sizes from any interventional trial. What is missing is any completed controlled trial of a pharmacological intervention, any validated patient stratification for the disease, and the funding needed to move beyond case reports and review protocols.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Modern Rheumatology Journal · 2022 · 4 citations · open access
Pigmented villonodular synovitis: literature review and case report
AbstractPigmented villonodular synovitis (PVNS) is a rare disease, its diagnosis has certain difficulties. This is due to the absence of characteristic etiological factors and clinical manifestations of PVNS, as well as the insufficient level of knowledge among doctors. The article presents a review of the literature on the diagnosis and treatment of PVNS, as well as a clinical case, which peculiarity is the late diagnosis of this disease, despite the presence of its certain clinical and morphological manifestations.
Acupuncture improves postoperative symptoms of pigmented villonodular synovitis： a protocol for systematic review and meta analysis
AbstractPigmented villonodular synovitis (PVNS) is a benign proliferative disease of synovial joint, synovial sac and tendon sheath. PVNS is usually treated by surgery, but postoperative joint dysfunction and pain will be accompanied, which seriously affect the quality of life.The purpose of this review is to evaluate the effectiveness and safety of this intervention in patients with pain and dysfunction caused by postoperative symptoms of PVNS.
Ein genetischer Faktor bei der pigmentierten villonodulären Synovitis?
AbstractThe aetiology of pigmented villonodular synovitis (PVNS) is unknown. The main hypothesis is based on two different interpretations of the histological changes. Suggested causes include response to blood and blood products from chronic repetitive trauma with repeated haemarthroses and inflammation as a response to an unknown trigger. Recent surveys suggest a benign neoplastic process of synovial vascular or fibrohistiocytic origin. This view is supported by some cytogenetic evidence of clonality. However, most authors favour a non-neoplastic aetiology. Although PVNS is uncommon we report on a father and son affection. Our observations suggest that genetic factors might also be important in the development of pigmented villonodular synovitis.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
